Protective effect of lodoxamide tromethamine on allergen inhalation challenge

Gavin D. Watt, Tiet C. Bui, Againdra K. Bewtra, Robert G. Townley

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Lodoxamide tromethamine (U-42,585E) is a new drug intended for prophylaxis of mast cell-mediated allergic disease. It is a water-soluble, cromolyn-like agent with demonstrated activity in rat peritoneal mast cell assay, rat percutaneous anaphylaxis (rat PCA) and sensitized rhesus monkey airway system. Ten allergen-sensitive asthmatics were pretreated with lodoxamide (0.01, 0.1, or 1.0 mg) or placebo, then challenged with serial dilutions of allergen extract. Analysis of allergen dose-response curve parameters shows that pretreatment with lodoxamide offers significant protection against experimental allergen-induced bronchoconstriction. At 0.01 mg, lodoxamide was effective in over half the subjects tested. Administration of lodoxamide by inhalation at doses of 0.1 and 1.0 mg uniformly allowed subjects to tolerate significantly larger doses of inhaled allergen. Side effects observed at these doses were minimal.

Original languageEnglish (US)
Pages (from-to)286-294
Number of pages9
JournalJournal of Allergy and Clinical Immunology
Issue number4
StatePublished - 1980

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Protective effect of lodoxamide tromethamine on allergen inhalation challenge'. Together they form a unique fingerprint.

Cite this